INDICATIONS

Nplate® is a thrombopoietin receptor agonist indicated for the treatment of thrombocytopenia in adult patients with immune thrombocytopenia (ITP) who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy. Nplate® is indicated for the treatment of thrombocytopenia in pediatric patients 1 year of age and older with ITP for at least 6 months who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy.


Nplate® is not indicated for the treatment of thrombocytopenia due to myelodysplastic syndrome (MDS) or any cause of thrombocytopenia other than ITP. Nplate® should be used only in patients with ITP whose degree of thrombocytopenia and clinical condition increase the risk for bleeding. Nplate® should not be used in an attempt to normalize platelet counts.

... Read More 
Nplate (romiplostim) out-of-pocket (OOP) costs
81% of Nplate® (romiplostim) claims have $0 out-of-pocket costs for the patient1,*

*Among the 19% of Nplate® claims where patients had out-of-pocket (OOP) costs, most claims (72%) had an OOP cost of less than $400. Data based on Symphony Health Solutions claims data. 24,199 Nplate® claims were identified between 1/1/2019 - 12/31/2019 for all payors, including commercial and government.1

Nplate® access, reimbursement, and patient support resources let you put your patients’ needs first


aa360 logo

SUPPORT FROM
EVERY ANGLE

Rely on Amgen Assist 360™, a single point of
contact, to provide support designed around
you and your patients.

Monday through Friday —
9:00 am to 8:00 pm ET

Learn about the Amgen Therapy Locator™
amgentherapylocator.com
document icon

Resources for your office

Benefit Verification

Submit, store, and retrieve benefit verifications for all patients currently on Amgen medications electronically with ease from our secure Amgen Assist 360™ Provider Portal.

Reimbursement Counselors

Call an Amgen Reimbursement Counselor directly for your benefit verification needs.

Field Reimbursement Specialists

Schedule a remote or live appointment with a Field Reimbursement Specialist who can assist with:

  • General reimbursement questions, including product coding and billing information
  • Prior authorization and claims denials/appeals
  • Payer-specific inquiries and policy updates
  • Financial assistance, including Amgen FIRST STEP™ co-pay program support

Resources for your patients

Nurse NAVIGATORS

Patients are connected with a single point of contact who can help them find resources that are most important to them.*​ Amgen Nurse Navigators are there to support, not replace, your treatment plan and are trained to assist a patient with financial coverage and emotional wellness throughout their treatment journey.

Referrals to day-to-day living resources

Patients can learn about independent nonprofit organizations that may provide community resources, one-on-one counseling services, and local support groups.

Financial and co‑pay assistance
  • For eligible commercially insured patients, the Amgen FIRST STEP™ co‑pay program can help. Please see details below
  • For patients with government insurance like Medicare, we provide referrals to independent nonprofit patient assistance programs that may be able to help them afford the co‑pay cost of their medicine*
  • For uninsured patients, the Amgen Safety Net Foundation, a nonprofit patient assistance program sponsored by Amgen, helps qualified patients access Amgen medicines at no cost

*Resources include referrals to independent nonprofit patient assistance programs. Eligibility for resources provided by independent nonprofit patient assistance programs is based on the nonprofit’s criteria. Amgen has no control over these programs and provides referrals as a courtesy only.

Patients should always consult their healthcare provider regarding medical decisions or treatment concerns.

Terms, conditions, and program maximums apply. This program is not open to patients receiving prescription reimbursement under any federal, state, or government-funded healthcare program. Not valid where prohibited by law.

§Amgen Assist 360™ can refer patients to independent nonprofit patient assistance programs that may be able to help them afford the co-pay costs for their prescribed medicine.


Amgen FIRST STEP™

For eligible* commercially insured patients

Amgen FIRST STEP™ can help your eligible commercially insured patients cover their out-of-pocket prescription costs, including deductible, co-insurance, and co-payment.

  • $0 out-of-pocket for first dose or cycle
  • As little as $5 out-of-pocket for subsequent doses of cycles, up to the brand program benefit maximum
  • No income eligibility requirement

Visit Amgen FIRST STEP™ now

*Terms, conditions, and program maximums apply. This program is not open to patients receiving prescription reimbursement under any federal, state, or government-funded healthcare program. Not valid where prohibited by law.

Help your patients enroll today!

Download enrollment form
There are three easy ways to
help patients submit
their
enrollment form for
Amgen Assist 360™
phone icon

Call 1‑888‑4ASSIST
(1‑888‑427‑7478)

Monday through Friday
9:00 am to 8:00 pm ET

fax icon

Fax 1‑866‑218‑4777

Mail Icon

Mail PO Box 220354
Charlotte, NC 28222‑9924

Connect with us

Monday through Friday —
9:00 am to 8:00 pm ET

Amgen Therapy Locator

Use this searchable database to locate alternative injection sites where Nplate® can be administered to your patients*

Visit Amgen Therapy Locator now

*The information on this website is reported by independent third-party treatment sites. It is not comprehensive of all sites that handle the therapies listed, and Amgen does not confirm accuracy or otherwise endorse any treatment sites.

Note: Coding and coverage policies change periodically and often without warning. The healthcare provider is solely responsible for determining coverage and reimbursement parameters and appropriate coding for his/her own patients and procedures. This information is not a guarantee of coverage or reimbursement.

Important Safety Information

Risk of Progression of Myelodysplastic Syndromes to Acute Myelogenous Leukemia

  • In Nplate® (romiplostim) clinical trials of patients with myelodysplastic syndromes (MDS) and severe thrombocytopenia, progression from MDS to acute myelogenous leukemia (AML) has been observed.
  • Nplate® is not indicated for the treatment of thrombocytopenia due to MDS or any cause of thrombocytopenia other than ITP.

Thrombotic/Thromboembolic Complications

  • Thrombotic/thromboembolic complications may result from increases in platelet counts with Nplate ® use. Portal vein thrombosis has been reported in patients with chronic liver disease receiving Nplate®.
  • To minimize the risk for thrombotic/thromboembolic complications, do not use Nplate ® in an attempt to normalize platelet counts. Follow the dose adjustment guidelines to achieve and maintain a platelet count of ≥ 50 x 109/L.

Loss of Response to Nplate®

  • Hyporesponsiveness or failure to maintain a platelet response with Nplate ® should prompt a search for causative factors, including neutralizing antibodies to Nplate ®.
  • To detect antibody formation, submit blood samples to Amgen (1‑800‑772‑64361‑800‑772‑6436). Amgen will assay these samples for antibodies to Nplate ® and thrombopoietin (TPO).
  • Discontinue Nplate® if the platelet count does not increase to a level sufficient to avoid clinically important bleeding after 4 weeks at the highest weekly dose of 10 mcg/kg.
Adverse Reactions
Adult ITP
  • In the placebo-controlled trials of adult ITP patients, headache was the most commonly reported adverse drug reaction, occurring in 35% of patients receiving Nplate® and 32% of patients receiving placebo. Adverse drug reactions in adults with a ≥ 5% higher patient incidence in Nplate® versus placebo were Arthralgia (26%, 20%), Dizziness (17%, 0%), Insomnia (16%, 7%), Myalgia (14%, 2%), Pain in Extremity (13%, 5%), Abdominal Pain (11%, 0%), Shoulder Pain (8%, 0%), Dyspepsia (7%, 0%), and Paresthesia (6%, 0%).
  • The safety profile of Nplate® was similar across patients, regardless of ITP duration. The following adverse reactions (at least 5% incidence and at least 5% more frequent with Nplate® compared with placebo or standard of care) occurred in Nplate ® patients with ITP duration up to 12 months: bronchitis, sinusitis, vomiting, arthralgia, myalgia, headache, dizziness, diarrhea, upper respiratory tract infection, cough, nausea and oropharyngeal pain. The adverse reaction of thrombocytosis occurred with an incidence of 2% in adults with ITP duration up to 12 months.
Pediatric ITP
  • The most common adverse reactions experienced by ≥ 5% of patients receiving Nplate ® with ≥ 5% higher incidence in the Nplate® arm across the two placebo-controlled trials were contusion (41%), upper respiratory tract infection (31%), oropharyngeal pain (25%), pyrexia (24%), diarrhea (20%), rash (15%), and upper abdominal pain (14%).
  • In pediatric patients of age ≥ 1 year receiving Nplate® for ITP, adverse reactions with an incidence of ≥ 25% in the two randomized trials were: contusion (41%), upper respiratory tract infection (31%), and oropharyngeal pain (25%).
  • In a long-term, single arm, open label pediatric safety study, headache occurred in 78/203 patients (38%); the incidence rates of other adverse reactions were similar to those reported in the placebo-controlled studies.

Nplate® administration may increase the risk for development or progression of reticulin fiber formation within the bone marrow. This formation may improve upon discontinuation of Nplate ®. In a clinical trial, one patient with ITP and hemolytic anemia developed marrow fibrosis with collagen during Nplate® therapy.

INDICATIONS

Nplate® is a thrombopoietin receptor agonist indicated for the treatment of thrombocytopenia in adult patients with immune thrombocytopenia (ITP) who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy. Nplate ® is indicated for the treatment of thrombocytopenia in pediatric patients 1 year of age and older with ITP for at least 6 months who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy.

Nplate® is not indicated for the treatment of thrombocytopenia due to myelodysplastic syndrome (MDS) or any cause of thrombocytopenia other than ITP. Nplate ® should be used only in patients with ITP whose degree of thrombocytopenia and clinical condition increase the risk for bleeding. Nplate ® should not be used in an attempt to normalize platelet counts.

Please see full Prescribing Information and Medication Guide.

Important Safety Information

Risk of Progression of Myelodysplastic Syndromes to Acute Myelogenous Leukemia

  • In Nplate® (romiplostim) clinical trials of patients with myelodysplastic syndromes (MDS) and severe thrombocytopenia, progression from MDS to acute myelogenous leukemia (AML) has been observed.
  • Nplate® is not indicated for the treatment of thrombocytopenia due to MDS or any cause of thrombocytopenia other than ITP.

Thrombotic/Thromboembolic Complications

  • Thrombotic/thromboembolic complications may result from increases in platelet counts with Nplate® use. Portal vein thrombosis has been reported in patients with chronic liver disease receiving Nplate®.
  • To minimize the risk for thrombotic/thromboembolic complications, do not use Nplate® in an attempt to normalize platelet counts. Follow the dose adjustment guidelines to achieve and maintain a platelet count of ≥ 50 x 109/L.

Loss of Response to Nplate®

Reference: 1. Data on file, Amgen; Patient OOP; 2019.